03/14/2019 | Press release | Distributed by Public on 03/14/2019 10:28
William Blair & Company issued a comprehensive report on allogenic cell therapies and initiated coverage of three companies participating in this area: Allogene Therapeutics, Inc. (ALLO $28.26), Cellectis S.A. (CLLS $18.36), and CRISPR Therapeutics AG (CRSP $39.04).
In his detailed report, analyst Raju Prasad wrote that 'with the robust efficacy of autologous chimeric antigen receptor (CAR)-T-cell therapies to date (Novartis's Kymriah and Gilead's Yescarta approved in the U.S. and E.U. and CAR-T cells targeting B-cell maturation antigen [BCMA], such as Celgene/bluebird bio's bb2121, showing impressive clinical results that will likely lead to regulatory approval in fourth-line multiple myeloma in 2020, with earlier lines potentially thereafter), the focus has shifted to commercial issues related to vein-to-vein time, manufacturing variability, shipping/chain-of-custody issues, and scalability over the long term. Allogeneic cell therapies (derived from a healthy donor) have the potential to address these issues by providing an enhanced speed to patient, availability, decreased cell variability, and streamlined manufacturing efficiencies. With a recent influx of investment in the space, we believe that the next phase of growth in the widespread use of cell therapies will be catalyzed by the successful development of these 'off-the-shelf' modalities.'
Prasad said he views Allogene as a 'core holding for investors looking for exposure to innovation in this subsector with de-risked initial targets and indications.'
'ALLO-501, Allogene's anti-CD19 allogeneic CAR-T, uses refined manufacturing and pre-conditioning processes with a proprietary anti-CD52 antibody (ALLO-647) that has shown potential to increase engraftment,' he said. 'Data from the company's Phase I trial is anticipated in first half 2020. UCART19, a partnered product with Servier, is an anti-CD19 allogeneic CAR-T being developed for ALL with promising data from a pooled analysis presented at ASH 2018: 82% CR/CRi with a lymphodepletion regimen of fludarabine, cyclophosphamide and alemtuzumab. We model $1.7 billion revenue for ALLO-501 in NHL and $483 million for UCART19 in ALL by 2030.'
Prasad said that in addition to Cellectis' collaboration with Servier/Allogene, the company has its own wholly owned pipeline of allogeneic CAR-T therapies. 'We see the company's UCART22 to be the most intriguing product in the wholly owned pipeline. This viewpoint stems from data on clinical remissions in patients treated with an autologous CD22 CAR-T that relapsed after treatment with CD19 CAR-T. Therefore, UCART22 could become a first-in-class allogeneic cell therapy for CD19-negative relapsed patients in ALL and NHL.'
CRISPR Therapeutics is focused on developing innovative therapies for serious diseases using CRISPR/Cas9 technology.
'The company's lead candidate, CTX001, co-developed with Vertex Pharmaceuticals, is an autologous CRISPR/Cas9 edited hematopoietic stem cell therapy being studied in a Phase I trial for the treatment of β-thalassemia and SCD,' Prasad said. 'CTX001 aims to upregulate fetal hemoglobin (HbF) to treat the underlying hemoglobin pathophysiology. Preclinical studies using healthy donor cells have shown CTX001 modifies over 90% of cells and increases HbF by over 30%. The company's pipeline also contains three, allogeneic, CRISPR-edited CAR-T products: CTX110 (anti-CD19) for the treatment of CD19+ malignancies such as NHL and ALL (clinical trial guided for initiation in first half 2019), CTX120 (anti-BCMA) for the treatment of MM, and CTX130 (anti-CD70) for the treatment of solid tumors and hematologic malignancies.'
William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients' evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.
William Blair or an affiliate does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. This report is not intended to provide personal investment advice. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments, or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein.
William Blair or an affiliate is a market maker in the securities of Allogene Therapeutics, Inc., Cellectis S.A., and CRISPR Therapeutics AG.
William Blair or an affiliate expects to receive or intends to seek compensation for investment banking services Allogene Therapeutics, Inc., Cellectis S.A., and CRISPR Therapeutics AG or an affiliate within the next three months.
Officers and employees of William Blair or its affiliates (other than research analysts) may have a financial interest in securities of Allogene Therapeutics, Inc., Cellectis S.A., and CRISPR Therapeutics AG.
Please contact us at +1 800 621 0687 or view disclosures on our coverage list.
Additional information is available upon request.
Current Ratings Distribution (as of 3/13/19)
Outperform (Buy): 67%
Market Perform (Hold): 32%
Underperform (Sell): 1%
Inv. Banking Relationships*
Outperform (Buy): 19%
Market Perform (Hold): 8%
Underperform (Sell): 0%
* Percentage of companies in each rating category that are investment banking clients, defined as companies for which William Blair has received compensation for investment banking services within the past 12 months.
The compensation of the research analyst is based on a variety of factors, including the quality and accuracy of research, client feedback, contributions to other firm departments, competitive factors, and firm profitability.
OTHER IMPORTANT DISCLOSURES
Stock ratings and valuation methodologies: William Blair & Company, L.L.C. uses a three-point system to rate stocks. Individual ratings reflect the expected performance of the stock relative to the broader market (generally the S&P 500, unless otherwise indicated) over the next 12 months. The assessment of expected performance is a function of near-, intermediate-, and long-term company fundamentals, industry outlook, confidence in earnings estimates, valuation (and our valuation methodology), and other factors. Outperform (O) - stock expected to outperform the broader market over the next 12 months; Market Perform (M) - stock expected to perform approximately in line with the broader market over the next 12 months; Underperform (U) - stock expected to under perform the broader market over the next 12 months; not rated (NR) - the stock is not currently rated. The valuation methodologies include (but are not limited to) price-to-earnings multiple (P/E), relative P/E (compared with the relevant market), P/E-to-growth-rate (PEG) ratio, market capitalization/revenue multiple, enterprise value/EBITDA ratio, discounted cash flow, and others. Stock ratings and valuation methodologies should not be used or relied upon as investment advice. Past performance is not necessarily a guide to future performance.
The ratings and valuation methodologies reflect the opinion of the individual analyst and are subject to change at any time.
Our salespeople, traders, and other professionals may provide oral or written market commentary, short-term trade ideas, or trading strategies-to our clients, prospective clients, and our trading desks-that are contrary to opinions expressed in this research report. Certain outstanding research reports may contain discussions or investment opinions relating to securities, financial instruments and/or issuers that are no longer current. Always refer to the most recent report on a company or issuer. Our asset management and trading desks may make investment decisions that are inconsistent with recommendations or views expressed in this report. We will from time to time have long or short positions in, act as principal in, and buy or sell the securities referred to in this report. Our research is disseminated primarily electronically, and in some instances in printed form. Research is simultaneously available to all clients. This research report is for our clients only. No part of this material may be copied or duplicated in any form by any means or redistributed without the prior written consent of William Blair & Company, L.L.C.
This is not in any sense an offer or solicitation for the purchase or sale of a security or financial instrument. The factual statements herein have been take from sources we believe to be reliable, but such statements are made without any representation as to accuracy or completeness or otherwise, except with respect to any disclosures relative to William Blair or its research analysts. Opinions expressed are our own unless otherwise stated and are subject to change without notice. Prices shown are approximate.
This material is distributed in the United Kingdom and the European Economic Area (EEA) by William Blair International, Ltd., authorized and regulated by the Financial Conduct Authority (FCA). William Blair International, Limited is a limited liability company registered in England and Wales with company number 03619027. This material is only directed and issued to persons regarded as Professional investors or equivalent in their home jurisdiction, or persons falling within articles 19 (5), 38, 47, and 49 of the Financial Services and Markets Act of 2000 (Financial Promotion) Order 2005 (all such persons being referred to as 'relevant persons'). This document must not be acted on or relied on by persons who are not 'relevant persons.'
'William Blair' and 'R*Docs' are registered trademarks of William Blair & Company, L.L.C. Copyright 2019, William Blair & Company, L.L.C. All rights reserved.